Western blot analysis of extracts from C2C12 cells, untreated (-) or treated with combinations of the following treatments as indicated: AICAR #9944 (2 mM, 24 hr; +) and Dorsomorphin (Compound C) (10 μM, 24 hr; +), using Phospho-AMPKα (Thr172) (40H9) Rabbit mAb #2535 (upper), AMPKα Antibody #2532 (middle), or β-Actin (D6A8) Rabbit mAb #8457 (lower).
Chemical structure of Dorsomorphin (Compound C).
Dorsomorphin (Compound C) is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 1.25 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|Molecular Weight||399.5 g/mol|
|Solubility||Soluble in DMSO at 4 mg/ml with warming.|
Dorsomorphin (Compound C) is a potent and reversible AMP-activated protein kinase (AMPK) inhibitor that competes with ATP in the absence of AMP with a Ki value of 109 nM (1). This small compound is selective, displaying no significant inhibition of other kinases inclusive of ZAPK, SYK, PKCθ, PKA, and JAK3 (1). Research has shown that Dorsomorphin (Compound C) inhibits tumor cell proliferation and induces apoptosis through mechanisms independent of the AMPK pathway (2). This compound inhibits the effects that AICAR and metformin have on inactivating acetyl-CoA carboxylase (ACC) and selectively inhibits the BMP type I receptors ALK2, ALK3, and ALK6 (1,3).